Meningococcal sugar as a helper to enhance performance of Group B vaccine candidates
Research archive
- University Medical Centre, Utrecht, The Netherlands
- Researchers:
Dr Jeanette Leusen, Dr Liana Steeghs
- Project Number: 0208.0
- Category: Prevention
- Duration: 24 month
- Start Date: 01 January 2008
- Type: Lay summary
- View scientific version
Components of the outer layer of Group B meningococcal bacteria provide the basis for several novel Group B vaccine candidates that are in development. Although many of them look promising, there have been some difficulties in getting the vaccines to stimulate a big enough immune response. This has led scientists to consider whether LPS, which provokes a big immune response, could be used to enhance these candidates. However, LPS is poisonous. The researchers have already found a way to alter the structure of LPS, so that it can still produce an immune reaction but is no longer toxic. The altered LPS could potentially be used in new vaccines but to make sure that is done safely and successfully, the researchers must first fully investigate the way in which altered LPS interacts with the different parts of the immune system.
Results from this study have been published in a scientific journal as follows:
Steeghs L, van Vliet SJ, Uronen-Hansson H, van Mourik A, Engering A, Sanchez-Hernandez M, Klein NJ, Callard R, van Putten JP, van der Ley P, van Kooyk Y, van de Winkel JG.
Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function.
Cell Microbiol 2006 Feb;8(2):316-25.
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1462-5822.2005.00623.x